Form 4: Lucid Diagnostics Director, Debra White, Acquires 112,800 Shares of Common Stock

Director Debra White acquired 112,800 shares of Lucid Diagnostics common stock on February 20, 2025, as part of a restricted stock grant.

Summary

• On February 20, 2025, Debra White, a director of Lucid Diagnostics Inc., acquired 112,800 shares of common stock.
• The acquisition was a result of a restricted stock grant under the Issuer's 2018 Equity Plan.
• The restricted stock vests on May 20, 2028, and is subject to forfeiture if the service period is not completed.
• Following the transaction, Debra White directly owns 112,800 shares of Lucid Diagnostics common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects a standard transaction filing, with the director's stock acquisition potentially viewed as a mildly positive signal.

Positives

• The acquisition of shares by a director can be seen as a positive sign, indicating confidence in the company's future prospects.

Risks

• The restricted stock is subject to forfeiture if the service period is not completed, which could impact the director's holdings.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance.

Industry Context

This filing is a routine disclosure related to insider transactions and provides limited insight into broader industry trends.

Stakeholder Impact

• The acquisition of shares by a director may have a slightly positive impact on shareholder sentiment.

Key Dates

Keywords

Lucid Diagnostics, Debra White, Director, Common Stock, Restricted Stock, Equity Plan, Beneficial Ownership, Form 4, Acquisition, Vesting